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Chapter 10 Valorisation 
The main results, practical findings, and policy recommendations of this dissertation 
can be relevant for a wide target audience: scientific, technical, business, institutional 
and governmental audiences as well as the general public at large. 
 
Effective communication, dissemination and exploitation of the results of this research 
are an essential part of the its success to reach the maximum social value creation. In 
addition, it is necessary to exployt a wide range of tools to reach such a diverse target 
audience. This tools includes publications in peer-reviewed journals (open acesses 
whever feasible), specialist website and presentations in scientific conferences and sem-
inars (scientific community); commercial, financial and industrial publications (busi-
ness organizations), popular newspapers, magazines, blogs, social media, and the Inter-
net (the general public); reports and policy briefs (international organisations and poli-
cy makers).  
 
In short, the social value created in this dissertation can be presented in three different, 
though connected, dimensions. 
10.1 Guidance for policy makers 
The topic of this dissertation is highly relevant in terms of public policy. Chapter 8 is 
entirely devoted to discuss the policy implications of the results presented along this 
book. The main call for action at the national level refers to the need of building ‘bar-
gain strengths’ in low and middle-income countries. To be able to negotiate better 
prices for patented medicines, local governments must have access to technological 
capabilities that are necessary either to manufacture the concerned drug or to develop 
its productive process.  
 
We acknowledge the existence of a wide variance in the actual development stage of the 
pharmaceutical industry in the developing world. Thus, different industrial policy 
approaches are suggested so that they can be more suitable for these different initial 
conditions. Although, this research does not provide a ready recipe for policy formula-
tion and implementation, it does address an important topic and provide general 
guidelines to solve (or alleviate) the problem at hand. 
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10.2 Orientation for business strategy 
Research-based pharmaceutical companies can also benefit from the results of this 
research. First, these companies can use the integrative framework developed in this 
dissertation to fine tune their strategy when negotiating prices with governments. 
Compulsory licensing is never an optimal solution for the patent holder. There-
fore, companies should address the sources of informational constrains and find the 
best response in terms of price reduction that they can offer without losing the 
market. 
 
In additional, corporations themselves are also observed to hold the view that they 
should go beyond their traditionally defined responsibilities to take up some of the 
social responsibilities. Moreover, affordable access to medicines in developing coun-
tries, through the cooperation of the pharmaceutical industry is a focal area of the 
MDGs and is include as part of the MDG 8.  
Engaging in price negotiation strategies with developing countries can be seen as robust 
intiatives in terms of CSR initiatives and brand trust and reputation, which in turn 
may create economic value for shareholders and social value for consumers.  
10.3 Raising Awareness  
The pharmaceutical industry invest heavily in R&D of products that may have a signif-
icant positive impact on individual and collective health. In many instances, pharma-
ceutical innovation makes the difference between live and death. For some dome dis-
eases, such as HIV/AIDS, even though they do not provide a cure, pharmaceutical 
products provide signifcant improvement not only in the life expanctancy in the quali-
ty of living of those extra years gained. However, many people – most of them in low 
and middle-income countries –  cannot enjoy the benefits from breakthrough drugs 
simply because they cannot affor these products. 
 
This research raises awareness not only of this important problem, but also of one of its 
causes and possible alternatives to solve or alleviate it. As pointed by Kingdon (2013),  
the chances for a problem to raise on the governmental agenda increase if a solution is 
attached to the it. In addition, the same author says that the chances for a problem to 
raise on decision-making agenda are dramatically increased if a solution is attached to 
it. Therefore, this research can make a real contribution to this topic outside the aca-
demic world. To realize this potential, it is necessary – though far from being sufficient 
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– to disseminate the results of this dissertation and to establish of a continuos dialogue 
with the scientific community, business sector, policy-makers and the general public. 
 
In additional, we joint the voices that call for changes in the institutional framework 
concerning compulsory licensing. The limitations imposed by the Paragraph 6 system 
constrain not only the existing possibilities for the use of compulsory licensing in price 
negotiations but also the design of policies to address this problem in the developing 
world. Therefore, our attempt to raise awareness to this topic may have relevant im-
plactions in terms of social value creation.  
